Institutional Career Development Core

联系PD/PI：Buchanan，托马斯A Inst-Career-Dev-001（724） 机构职业发展 项目总结/摘要 南加州临床转化研究所的个人职业发展（ICD）计划 在南加州大学和洛杉矶儿童医院内运作。我们的业务范围 位于洛杉矶的中心地带，85%的居民来自代表性不足的少数民族，20%的人生活在 在联邦贫困线上，30%的人在18岁以下，57%的成年人没有完成高中学业。疾病 负担很高，并因与贫困、犯罪、语言障碍和文化有关的健康差距而加剧。 信仰因此，我们的目标是：1）培养领导者谁进行严格的和可重复的临床翻译 研究（CTR），确定和克服转化障碍，以改善健康的多样性 人口，2）使学者能够维持CTR职业生涯，以及3）增加学者多样性，以更有效地 满足我们不同社区的健康需求。基于这些目标，我们扩展了ICD机构 拥有最先进的教育和导师资源中心以及咨询和教师委员会的生态系统 拥有强大的教育CTR专业知识和更广泛的URM代表。我们建议培训4名新学者 每年通过NIH，机构和部门基金进行三年。ICD计划建立在 成功的三个课程系列强调CTR研究方法，严谨性和可重复性，团队 科学，沟通技巧，在不同人群的研究，结合全面的职业生涯 发展计划。学者报名参加临床，生物医学和生物医学硕士或证书课程， 翻译研究。新的ICD培训机会包括医疗保健提供科学，健康数据 科学、精准医疗和质量源于设计。一个强大的远程教育平台已经到位， 记录，存档和传播教育材料;它还支持学者在发展口头 沟通技巧和传播他们的研究。体验机会包括与SC的互动 CTSI核心专家，例如，数字招聘，社区参与，监管知识，社区 导师，并访问学者在其他CTSA机构的研究报告。奖学金导师团队使用 个人发展计划，以指导整个计划的职业发展。职业障碍 通过一个新的障碍缓解委员会来确定和解决进展，该委员会通知学者们， 长期职业成功的韧性。我们建立了强大的跟踪和评估流程， 并推进该计划。数据显示，由于ICD学者， 和校友过渡到独立的研究事业与强大的研究资金，学术生产力， 和进步。更广泛地说，我们在区域和国家一级为培训和职业发展做出了贡献。 通过共享工具和最佳实践以及在CTSA委员会中的领导作用， 组我们期待在下一个融资周期扩大这一成功。

Contact PD/PI: Buchanan, Thomas A Inst-Career-Dev-001 (724) INSTITUTIONAL CAREER DEVELOPMENT Project Summary/Abstract The Southern California Clinical Translational Institute's Individual Career Development (ICD) Program operates within the University of Southern California and Children's Hospital Los Angeles. We operate in the heart of Los Angeles, where 85% of residents are from underrepresented minority groups, 20% live below the federal poverty level, 30% are under 18 years old, and 57% of adults do not complete high school. The disease burden is high and amplified by health disparities linked to poverty, crime, language barriers, and cultural beliefs. Thus, we aim to: 1) develop leaders who conduct rigorous and reproducible clinical translational research (CTR) that identifies and overcomes translational barriers to improve the health of diverse populations, 2) empower Scholars to sustain CTR careers, and 3) increase Scholar diversity to more effectively address our diverse communities' health needs. Based on these aims, we expand the ICD Institutional Ecosystem with state-of-the-art Education and Mentor Resource Centers and Advisory and Faculty Boards with strong educational CTR expertise and broader URM representation. We propose to train 4 new Scholars per year for three years each through NIH, institutional, and departmental funds. The ICD Program builds on a successful three-course series emphasizing CTR research methodology, rigor and reproducibility, team science, communication skills, and research in diverse populations, combined with a comprehensive career development program. Scholars enroll in a Master's or Certificate program in Clinical, Biomedical, and Translational Investigations. New ICD training opportunities include healthcare delivery science, health data science, precision medicine, and Quality by Design. A robust distance education platform is in place for recording, archiving, and disseminating educational materials; it also supports Scholars in developing oral communication skills and disseminating their research. Experiential opportunities include interactions with SC CTSI core experts in, e.g., digital recruitment, community engagement, regulatory knowledge, community mentors, and visiting scholar research presentations at other CTSA institutions. Scholars-Mentor teams use Individual Development Plans to guide career progression throughout the program. Barriers to career progression are identified and addressed through a novel Barriers Mitigation Board which informs scholars' resilience for long-term career success. We have created robust tracking and evaluation processes that inform and advance the program. Data show transformative and widespread institutional change due to ICD Scholars and alumni transitioning to independent research careers with robust research funding, academic productivity, and advancement. More broadly, we have contributed regionally and nationally to training and career development in CTR by sharing tools and best practices and leadership in CTSA committees and working groups. We look forward to expanding this success in the next funding cycle.